Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
Background: Despite the guidelines for Economic and Public Health Assessment Committee (CEESP) submission having been available for nearly six years, the dossiers submitted continue to deviate from them, potentially impacting product prices. Objective: to review the reports published by CEESP, analy...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2017.1344088 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045533418160128 |
|---|---|
| author | Mondher Toumi Anastasiia Motrunich Aurélie Millier Cécile Rémuzat Christos Chouaid Bruno Falissard Samuel Aballéa |
| author_facet | Mondher Toumi Anastasiia Motrunich Aurélie Millier Cécile Rémuzat Christos Chouaid Bruno Falissard Samuel Aballéa |
| author_sort | Mondher Toumi |
| collection | DOAJ |
| description | Background: Despite the guidelines for Economic and Public Health Assessment Committee (CEESP) submission having been available for nearly six years, the dossiers submitted continue to deviate from them, potentially impacting product prices. Objective: to review the reports published by CEESP, analyse deviations from the guidelines, and discuss their implications for the pricing and reimbursement process. Study design: CEESP reports published until January 2017 were reviewed, and deviations from the guidelines were extracted. The frequency of deviations was described by type of methodological concern (minor, important or major). Results: In 19 reports, we identified 243 methodological concerns, most often concerning modelling, measurement and valuation of health states and results presentation and sensitivity analyses; nearly 63% were minor, 33% were important and 4.5% were major. All reports included minor methodological concerns, and 17 (89%) included at least one important and/or major methodological concern. Global major methodological concerns completely invalidated the analysis in seven dossiers (37%). Conclusion: The CEESP submission dossiers fail to adhere to the guidelines, potentially invalidating the health economics analysis and resulting in pricing negotiations. As these negotiations tend to be unfavourable for the manufacturer, the industry should strive to improve the quality of the analyses submitted to CEESP. |
| format | Article |
| id | doaj-art-421e4fb95777415d8526bb30376507cb |
| institution | DOAJ |
| issn | 2001-6689 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-421e4fb95777415d8526bb30376507cb2025-08-20T02:54:40ZengMDPI AGJournal of Market Access & Health Policy2001-66892017-01-015110.1080/20016689.2017.13440881344088Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessmentMondher Toumi0Anastasiia Motrunich1Aurélie Millier2Cécile Rémuzat3Christos Chouaid4Bruno Falissard5Samuel Aballéa6Aix-Marseille Université, Université de la MéditerranéeHealth Economics and Outcomes Research Department, Creativ-CeuticalHealth Economics and Outcomes Research Department, Creativ-CeuticalHealth Economics and Outcomes Research Department, Creativ-CeuticalINSERM U955 and Université Paris Est (UPEC)UMR U955University Paris-SudAix-Marseille Université, Université de la MéditerranéeBackground: Despite the guidelines for Economic and Public Health Assessment Committee (CEESP) submission having been available for nearly six years, the dossiers submitted continue to deviate from them, potentially impacting product prices. Objective: to review the reports published by CEESP, analyse deviations from the guidelines, and discuss their implications for the pricing and reimbursement process. Study design: CEESP reports published until January 2017 were reviewed, and deviations from the guidelines were extracted. The frequency of deviations was described by type of methodological concern (minor, important or major). Results: In 19 reports, we identified 243 methodological concerns, most often concerning modelling, measurement and valuation of health states and results presentation and sensitivity analyses; nearly 63% were minor, 33% were important and 4.5% were major. All reports included minor methodological concerns, and 17 (89%) included at least one important and/or major methodological concern. Global major methodological concerns completely invalidated the analysis in seven dossiers (37%). Conclusion: The CEESP submission dossiers fail to adhere to the guidelines, potentially invalidating the health economics analysis and resulting in pricing negotiations. As these negotiations tend to be unfavourable for the manufacturer, the industry should strive to improve the quality of the analyses submitted to CEESP.http://dx.doi.org/10.1080/20016689.2017.1344088Health technology assessmentHTAHASCEESPefficiency opinionpricinghealth economics analysisHAS guidelines |
| spellingShingle | Mondher Toumi Anastasiia Motrunich Aurélie Millier Cécile Rémuzat Christos Chouaid Bruno Falissard Samuel Aballéa Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment Journal of Market Access & Health Policy Health technology assessment HTA HAS CEESP efficiency opinion pricing health economics analysis HAS guidelines |
| title | Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment |
| title_full | Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment |
| title_fullStr | Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment |
| title_full_unstemmed | Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment |
| title_short | Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment |
| title_sort | analysis of health economics assessment reports for pharmaceuticals in france understanding the underlying philosophy of ceesp assessment |
| topic | Health technology assessment HTA HAS CEESP efficiency opinion pricing health economics analysis HAS guidelines |
| url | http://dx.doi.org/10.1080/20016689.2017.1344088 |
| work_keys_str_mv | AT mondhertoumi analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment AT anastasiiamotrunich analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment AT aureliemillier analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment AT cecileremuzat analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment AT christoschouaid analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment AT brunofalissard analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment AT samuelaballea analysisofhealtheconomicsassessmentreportsforpharmaceuticalsinfranceunderstandingtheunderlyingphilosophyofceespassessment |